KR20070093006A - 5-메틸-1-페닐-2-(1h)-피리돈을 활성 성분으로서 함유하는의약 제제 - Google Patents
5-메틸-1-페닐-2-(1h)-피리돈을 활성 성분으로서 함유하는의약 제제 Download PDFInfo
- Publication number
- KR20070093006A KR20070093006A KR1020077018953A KR20077018953A KR20070093006A KR 20070093006 A KR20070093006 A KR 20070093006A KR 1020077018953 A KR1020077018953 A KR 1020077018953A KR 20077018953 A KR20077018953 A KR 20077018953A KR 20070093006 A KR20070093006 A KR 20070093006A
- Authority
- KR
- South Korea
- Prior art keywords
- weight
- tablet
- pyridone
- methyl
- phenyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2813—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/282—Organic compounds, e.g. fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Inorganic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
성분 | 양 | 주(註) |
피르페니돈 | 200.0 mg | |
락토오스 | 56.0 mg | |
카르멜로스 칼슘 | 20.0 mg | 과립내: 5.0 mg 과립외: 15.0 mg |
히드록시프로필셀룰로오스 | 6.0 mg | |
스테아르산마그네슘 | 3.0 mg | |
플레인 정제의 총 중량 285.0 mg | ||
히드록시프로필메틸셀룰로오스 2910 | 6.67 mg | |
산화티탄 | 2.66 mg | |
트리에틸 시트레이트 | 0.67 mg | |
스테아르산마그네슘 | 미량 | 0.02 mg |
활석 | 미량 | 0.02 mg |
코팅의 총 중량 10.00 mg | ||
코팅 정제의 총 중량 295.0 mg |
표본 | 색상차 (ΔE) | 변색 |
약물 물질 | 0.73 | 약간 |
압착 약물 물질 | 3.62 | 현저함 |
플레인 정제 | 5.08 | 현저함 |
코팅 정제 | 0.75 | 약간 |
Claims (4)
- 5-메틸-1-페닐-2-(1H)-피리돈을 주성분으로 함유하는 정제로서,상기 주성분의 함량이 200 mg 내지 400 mg이고, 상기 주성분을 기준으로, 10 내지 50 중량% 의 락토오스, 5 내지 40 중량% 의 카르멜로스 칼슘, 1 내지 10 중량% 의 히드록시프로필셀룰로오스 및 0.5 내지 5 중량% 의 스테아르산마그네슘을 함유하는 플레인 정제, 및 상기 주성분을 기준으로, 2 내지 6 중량% 의 히드록시프로필메틸셀룰로오스, 0.01 내지 1 중량% 의 트리에틸 시트레이트 및 0.05 내지 3 중량% 의 산화티탄을 함유하는 코팅층을 포함하는 정제.
- 제 1 항에 있어서, 상기 주성분을 기준으로 20 내지 30 중량% 의 락토오스, 7.5 내지 15 중량% 의 카르멜로스 칼슘, 2 내지 5 중량% 의 히드록시프로필셀룰로오스 및 0.5 내지 3 중량% 의 스테아르산마그네슘을 함유하는 플레인 정제, 및 상기 주성분을 기준으로 2 내지 4 중량% 의 히드록시프로필메틸셀룰로오스, 0.01 내지 1 중량% 의 트리에틸 시트레이트 및 0.8 내지 3 중량% 의 산화티탄을 함유하는 코팅층을 포함하는 정제.
- 5-메틸-1-페닐-2-(1H)-피리돈을 주성분으로 함유하는 295 mg 정제로서,상기 주성분의 함량이 200 mg이고, 56 mg의 락토오스, 20 mg의 카르멜로스 칼슘, 6.0 mg의 히드록시프로필셀룰로오스 및 3 mg의 스테아르산마그네슘을 함유하 는 플레인 정제, 및 6.67 mg의 히드록시프로필메틸셀룰로오스, 0.67 mg의 트리에틸 시트레이트, 2.66 mg의 산화티탄, 0.02 mg의 스테아르산마그네슘 및 0.02 mg의 활석을 함유하는 코팅층을 포함하는 정제.
- 하기 공정을 포함하는 것을 특징으로 하는, 5-메틸-1-페닐-2-(1H)-피리돈을 함유하는 정제의 제조 방법:A) 5-메틸-1-페닐-2-(1H)-피리돈, 락토오스 및 카르멜로스 칼슘를 함유하는 혼합 분말에 유동층 제립기로 히드록시프로필셀룰로오스를 분무하여 제립함으로써 과립을 수득하는 공정;B) 상기 수득한 과립에 카르멜로스 칼슘과 스테아르산마그네슘을 혼합한 후 11 내지 15 kN 의 힘으로 압축하여 5-메틸-1-페닐-2-(1H)-피리돈 플레인 정제를 수득하는 공정;C) 히드록시프로필메틸셀룰로오스, 트리에틸 시트레이트 및 산화티탄을 함유하는 코팅 용액을 상기 플레인 정제에 코팅하는 공정.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JPJP-P-2001-00019393 | 2001-01-29 | ||
JP2001019393 | 2001-01-29 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020037009856A Division KR100777169B1 (ko) | 2001-01-29 | 2002-01-25 | 5-메틸-1-페닐-2-(1h)-피리돈을 활성 성분으로서함유하는 의약 제제 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20070093006A true KR20070093006A (ko) | 2007-09-14 |
KR100891887B1 KR100891887B1 (ko) | 2009-04-03 |
Family
ID=18885277
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020037009856A KR100777169B1 (ko) | 2001-01-29 | 2002-01-25 | 5-메틸-1-페닐-2-(1h)-피리돈을 활성 성분으로서함유하는 의약 제제 |
KR1020077018953A KR100891887B1 (ko) | 2001-01-29 | 2002-01-25 | 5-메틸-1-페닐-2-(1h)-피리돈을 활성 성분으로서 함유하는의약 제제 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020037009856A KR100777169B1 (ko) | 2001-01-29 | 2002-01-25 | 5-메틸-1-페닐-2-(1h)-피리돈을 활성 성분으로서함유하는 의약 제제 |
Country Status (8)
Country | Link |
---|---|
US (7) | US7867516B2 (ko) |
EP (1) | EP1356816B1 (ko) |
JP (1) | JP4077320B2 (ko) |
KR (2) | KR100777169B1 (ko) |
AT (1) | ATE452637T1 (ko) |
DE (1) | DE60234812D1 (ko) |
TW (1) | TWI314868B (ko) |
WO (1) | WO2002060446A1 (ko) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101453688B1 (ko) * | 2013-11-05 | 2014-11-04 | 포항공과대학교 산학협력단 | 광 입사 각도 선택성을 가지는 전자 소자 및 그 제조 방법 |
WO2018160011A1 (ko) * | 2017-03-02 | 2018-09-07 | 영진약품 주식회사 | 피르페니돈의 입자크기 조절에 따른 타정성이 개선된 약제학적 조성물 및 이의 제조방법 |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100777169B1 (ko) | 2001-01-29 | 2007-11-16 | 시오노기세이야쿠가부시키가이샤 | 5-메틸-1-페닐-2-(1h)-피리돈을 활성 성분으로서함유하는 의약 제제 |
WO2005020961A1 (en) * | 2003-08-28 | 2005-03-10 | Sandoz Ag | Pharmaceutical composition comprising anticonvulsant with taste mask coating |
JP2005187339A (ja) * | 2003-12-24 | 2005-07-14 | Iwaki Seiyaku Co Ltd | 耐光性塩酸テルビナフィンフィルムコート錠 |
ES2524922T3 (es) | 2005-05-10 | 2014-12-15 | Intermune, Inc. | Derivados de piridona para modular el sistema de proteína cinasa activada por estrés |
NZ591443A (en) | 2005-09-22 | 2013-04-26 | Intermune Inc | Granule formation of pirfenidone and pharmaceutically acceptable excipients |
US20070203202A1 (en) * | 2005-12-02 | 2007-08-30 | Robinson Cynthia Y | Methods of reducing adverse events associated with pirfenidone therapy |
ES2581844T3 (es) | 2006-12-18 | 2016-09-07 | Intermune, Inc. | Método para proporcionar una terapia de pirfenidona a un paciente |
US20080287508A1 (en) * | 2007-05-18 | 2008-11-20 | Intermune, Inc. | Altering pharmacokinetics of pirfenidone therapy |
JP5248040B2 (ja) | 2007-05-25 | 2013-07-31 | リードケミカル株式会社 | 5−メチル−1−フェニル−2−(1h)−ピリドン含有貼付剤 |
MX2007009796A (es) | 2007-08-14 | 2009-02-25 | Cell Therapy And Technology S | Gel conteniendo pirfenidona. |
EP2296653B1 (en) | 2008-06-03 | 2016-01-27 | Intermune, Inc. | Compounds and methods for treating inflammatory and fibrotic disorders |
JP2010120912A (ja) | 2008-11-21 | 2010-06-03 | Lead Chemical Co Ltd | 5−メチル−1−フェニル−2−(1h)−ピリドン含有貼付剤 |
WO2010114404A1 (en) | 2009-04-01 | 2010-10-07 | Bial - Portela & Ca., S.A. | Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making thereof |
US20100256194A1 (en) * | 2009-04-01 | 2010-10-07 | Bial - Portela & Ca, S.A. | Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making the same |
CN101972236A (zh) * | 2010-10-13 | 2011-02-16 | 北京诚创康韵医药科技有限公司 | 一种含吡非尼酮的缓释制剂 |
US10105356B2 (en) | 2011-01-31 | 2018-10-23 | Avalyn Pharma Inc. | Aerosol pirfenidone and pyridone analog compounds and uses thereof |
JP6021117B2 (ja) | 2011-01-31 | 2016-11-02 | ジェノア ファーマシューティカルズ,インク. | エアロゾルのピルフェニドンおよびピリドンアナログの化合物、および、その使用 |
MX2011007675A (es) | 2011-07-19 | 2012-07-11 | Cell Therapy And Technology S A De C V | Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas. |
WO2013123419A1 (en) * | 2012-02-16 | 2013-08-22 | Teva Pharmaceutical Industries Ltd. | N-ethyl-n-phenyl-1,2-dihydro-4,5-di-hydroxy-1-methyl-2-oxo-3-quinoline carboxamide, preparation and uses thereof |
MX346763B (es) | 2012-03-28 | 2017-03-31 | Cell Therapy And Tech S A De C V | Composición tópica semisólida conteniendo pirfenidona y dialil óxido de disulfuro modificado (odd-m) para eliminar o prevenir el acné. |
MX356551B (es) | 2012-08-23 | 2018-06-04 | Grupo Medifarma S A De C V Star | Composición antiséptica, antiseborreica y exfoliante para eliminar o prevenir el acné. |
AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
EP3091976A4 (en) | 2014-01-10 | 2017-10-11 | Genoa Pharmaceuticals Inc. | Aerosol pirfenidone and pyridone analog compounds and uses thereof |
US10233195B2 (en) | 2014-04-02 | 2019-03-19 | Intermune, Inc. | Anti-fibrotic pyridinones |
CA2937365C (en) * | 2016-03-29 | 2018-09-18 | F. Hoffmann-La Roche Ag | Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same |
TWI745396B (zh) | 2016-07-12 | 2021-11-11 | 日商鹽野義製藥股份有限公司 | 吸入用醫藥組成物 |
MX364040B (es) * | 2016-11-11 | 2019-04-11 | Cell Therapy And Tech S A De C V | Uso farmacéutico de una composición que contiene pirfenidona de liberación prolongada (pfd-lp) para la reversión y tratamiento de la esteatohepatitis humana (nafld/nash). |
WO2018139626A1 (ja) | 2017-01-30 | 2018-08-02 | 塩野義製薬株式会社 | キナゾリン誘導体を含有する固形製剤 |
CN109223723B (zh) * | 2017-07-11 | 2021-08-27 | 南京华威医药科技集团有限公司 | 吡非尼酮片剂及其制备方法和用途 |
MX366086B (es) | 2017-08-15 | 2019-06-27 | Cell Therapy And Tech S A De C V | Composicion topica semisolida conteniendo un agente antimicrobiano y pirfenidona para el tratamiento de daños cronicos de la piel. |
TWI795462B (zh) | 2017-11-17 | 2023-03-11 | 日商鹽野義製藥股份有限公司 | 光安定性及溶出性優異的醫藥製劑 |
PT3511001T (pt) | 2018-01-12 | 2021-12-29 | Tiefenbacher Alfred E Gmbh & Co Kg | Formulação de comprimido e cápsula contendo pirfenidona |
WO2021215856A1 (ko) * | 2020-04-22 | 2021-10-28 | 영진약품 주식회사 | 안전성과 안정성이 개선된 피르페니돈을 포함하는 장용성 제제 및 이의 제조방법 |
WO2023161668A1 (en) | 2022-02-28 | 2023-08-31 | Nuformix Technologies Limited | Compositions and methods for treatment of idiopathic pulmonary fibrosis |
Family Cites Families (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4042699A (en) | 1972-12-18 | 1977-08-16 | Affiliated Medical Research, Inc. | Method for reducing serum glucose levels |
CA1049411A (en) * | 1972-12-18 | 1979-02-27 | Affiliated Medical Research | N-substituted pyridone and general method for preparing pyridones |
US4052509A (en) | 1972-12-18 | 1977-10-04 | Affiliated Medical Research, Inc. | Method for reducing serum uric acid levels |
CA1261835A (en) | 1984-08-20 | 1989-09-26 | Masaaki Toda | (fused) benz(thio)amides |
US4753801A (en) * | 1985-10-25 | 1988-06-28 | Eli Lilly And Company | Sustained release tablets |
US5271946A (en) * | 1988-04-20 | 1993-12-21 | Asta Pharma Aktiengesellschaft | Controlled release azelastine-containing pharmaceutical compositions |
JPH02215719A (ja) | 1989-02-15 | 1990-08-28 | Yamauchi Akitomo | 線維化病変組織の修復並びに線維化病変の阻止剤 |
US5716632A (en) | 1989-11-22 | 1998-02-10 | Margolin; Solomon B. | Compositions and methods for reparation and prevention of fibrotic lesions |
US5518729A (en) | 1989-11-22 | 1996-05-21 | Margolin; Solomon B. | Compositions and methods for reparation and prevention of fibrotic lesions |
US5310562A (en) * | 1989-11-22 | 1994-05-10 | Margolin Solomon B | Composition and method for reparation and prevention of fibrotic lesions |
EP0702551B1 (en) * | 1993-05-07 | 2002-09-25 | MARGOLIN, Solomon B. | Compositions and methods for reparation and prevention of fibrotic lesions |
CA2164344C (en) * | 1993-08-30 | 2004-06-29 | Stanley Lech | Tablet coating based on a melt-spun mixture of a saccharide and a polymer |
US5591766A (en) * | 1993-12-03 | 1997-01-07 | Cheil Foods & Chemicals, Inc. | Solid oral formulations of pyridone carboxylic acids |
US5639754A (en) | 1994-07-12 | 1997-06-17 | Janssen Pharmaceutica N.V. | Urea and thiourea derivatives of azolones |
CA2202058C (en) | 1994-10-07 | 2007-11-06 | Hidenori Ohki | Cyclic hexapeptides having antibiotic activity |
US6090822A (en) | 1995-03-03 | 2000-07-18 | Margolin; Solomon B. | Treatment of cytokine growth factor caused disorders |
JP3195361B2 (ja) | 1995-06-21 | 2001-08-06 | 塩野義製薬株式会社 | ビシクロ環系アミノ誘導体およびそれを含有するpgd2拮抗剤 |
JPH091787A (ja) * | 1995-06-22 | 1997-01-07 | Canon Inc | 印字装置 |
US5681382A (en) | 1995-08-22 | 1997-10-28 | Shin-Etsu Chemical Co., Ltd. | Rapidly soluble coating composition and method for preparing same |
BR9610480A (pt) * | 1995-09-19 | 1999-03-16 | Solomon Begelfor Margolin | Inibição do fator alfa de necrose tumoral |
US5962478A (en) | 1995-09-19 | 1999-10-05 | Margolin; Solomon B. | Inhibition of tumor necrosis factor α |
TW580397B (en) * | 1997-05-27 | 2004-03-21 | Takeda Chemical Industries Ltd | Solid preparation |
ATE241341T1 (de) * | 1997-09-10 | 2003-06-15 | Takeda Chemical Industries Ltd | Stabilisierte pharmazeutische zusammensetzung |
AU3731699A (en) * | 1998-05-18 | 1999-12-06 | Takeda Chemical Industries Ltd. | Orally disintegrable tablets |
WO2001066551A2 (en) | 2000-03-07 | 2001-09-13 | Ranbaxy Laboratories Limited | Azole compounds as therapeutic agents for fungal infections |
CA2403594A1 (en) | 2000-03-27 | 2002-09-18 | Kyowa Hakko Kogyo Co., Ltd. | Granules having good taking property |
EP1301484A2 (en) | 2000-07-20 | 2003-04-16 | Neurogen Corporation | Capsaicin receptor ligands |
CA2423329A1 (en) | 2000-09-22 | 2003-03-20 | Takeda Chemical Industries, Ltd. | Solid preparations |
KR100777169B1 (ko) | 2001-01-29 | 2007-11-16 | 시오노기세이야쿠가부시키가이샤 | 5-메틸-1-페닐-2-(1h)-피리돈을 활성 성분으로서함유하는 의약 제제 |
ATE460163T1 (de) | 2001-04-12 | 2010-03-15 | Pharmacopeia Llc | Arly und diaryl piperidinderivate verwendbar als mch-hemmer |
WO2002087549A1 (fr) | 2001-04-25 | 2002-11-07 | Taisho Pharmaceutical Co., Ltd. | Comprimes a liberation prolongee du type a unites multiples |
JP2005519876A (ja) | 2001-11-27 | 2005-07-07 | メルク エンド カムパニー インコーポレーテッド | 2−アミノキノリン化合物 |
EP2033951A3 (en) | 2002-02-01 | 2009-12-23 | Euro-Celtique S.A. | 2-Piperazine-pyridines useful for treating pain |
US6974818B2 (en) | 2002-03-01 | 2005-12-13 | Euro-Celtique S.A. | 1,2,5-thiadiazol-3-YL-piperazine therapeutic agents useful for treating pain |
CA2491079C (en) | 2002-06-28 | 2011-10-04 | Donald J. Kyle | Therapeutic piperazine derivatives useful for treating pain |
US7262194B2 (en) | 2002-07-26 | 2007-08-28 | Euro-Celtique S.A. | Therapeutic agents useful for treating pain |
JP2006502153A (ja) | 2002-08-27 | 2006-01-19 | インターミューン インコーポレイティッド | 特発性肺線維症の治療方法 |
US20060110358A1 (en) | 2002-08-28 | 2006-05-25 | Hsu Henry H | Combination therapy for treatment of fibrotic disorders |
US7157462B2 (en) | 2002-09-24 | 2007-01-02 | Euro-Celtique S.A. | Therapeutic agents useful for treating pain |
CA2501539A1 (en) | 2002-10-17 | 2004-04-29 | Amgen Inc. | Benzimidazole derivatives and their use as vanilloid receptor ligands |
US7582635B2 (en) | 2002-12-24 | 2009-09-01 | Purdue Pharma, L.P. | Therapeutic agents useful for treating pain |
RS20050714A (sr) | 2003-03-31 | 2008-04-04 | Pliva-Lachema A.S., | Farmaceutski preparati koji kao aktivnu suptancu sadrže kompleks platine i postupci za njihovo dobijanje |
US20050008691A1 (en) | 2003-05-14 | 2005-01-13 | Arturo Siles Ortega | Bicalutamide compositions |
US20070092488A1 (en) | 2003-05-16 | 2007-04-26 | Intermune Inc. | Methods of treating idiopathic pulmonary fibrosis |
EP1633317A4 (en) | 2003-05-16 | 2008-08-20 | Intermune Inc | Synthetic chemokine receptor ligands and methods of use therefor |
AR044688A1 (es) | 2003-06-12 | 2005-09-21 | Euro Celtique Sa | Agentes terapeuticos utiles para el tratamiento del dolor |
BRPI0412190A (pt) | 2003-07-01 | 2006-08-22 | Pharmacia & Upjohn Co Llc | sólidos com camada de difusão modulada |
KR100977242B1 (ko) | 2003-07-24 | 2010-08-24 | 유로-셀띠끄 소시에떼 아노님 | 피페리딘 화합물 및 그들을 포함하는 약학적 조성물 |
MXPA06000940A (es) | 2003-07-24 | 2006-03-30 | Euro Celtique Sa | Agentes terapeuticos utiles para el tratamiento de dolor. |
AU2004261666B2 (en) | 2003-08-01 | 2009-06-18 | Euro-Celtique S.A. | Therapeutic agents useful for treating pain |
JP4630871B2 (ja) | 2003-09-22 | 2011-02-09 | ユーロ−セルティーク エス.エイ. | 疼痛を治療するのに有用な治療薬 |
CA2537010A1 (en) | 2003-09-22 | 2005-04-07 | Euro-Celtique S.A. | Phenyl - carboxamide compounds useful for treating pain |
WO2005040758A2 (en) | 2003-10-24 | 2005-05-06 | Intermune, Inc. | Use of pirfenidone in therapeutic regimens |
WO2005047256A1 (fr) | 2003-11-14 | 2005-05-26 | Shanghai Genomics, Inc. | Derives de pyridone, et utilisation correspondante |
US7592373B2 (en) | 2003-12-23 | 2009-09-22 | Boehringer Ingelheim International Gmbh | Amide compounds with MCH antagonistic activity and medicaments comprising these compounds |
EA200601249A1 (ru) | 2003-12-30 | 2007-02-27 | Еуро-Селтик С. А. | Пиперазины, пригодные для лечения боли |
SE0400235D0 (sv) | 2004-02-06 | 2004-02-06 | Active Biotech Ab | New composition containing quinoline compounds |
US8642079B2 (en) | 2004-02-23 | 2014-02-04 | Hormos Medical Corporation | Solid formulations of ospemifene |
US7605176B2 (en) | 2004-03-06 | 2009-10-20 | Boehringer Ingelheim International Gmbh | β-ketoamide compounds with MCH antagonistic activity |
KR100966749B1 (ko) | 2004-05-26 | 2010-06-30 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 신나미드 화합물 |
US20090148407A1 (en) | 2005-07-25 | 2009-06-11 | Intermune, Inc. | Novel Macrocyclic Inhibitors of Hepatitis C Virus Replication |
NZ591443A (en) | 2005-09-22 | 2013-04-26 | Intermune Inc | Granule formation of pirfenidone and pharmaceutically acceptable excipients |
EP1959944A1 (en) | 2005-12-15 | 2008-08-27 | Shionogi Co., Ltd. | A pharmaceutical composition comprising an amide derivative |
ME02123B (me) | 2007-04-27 | 2014-08-29 | Purdue Pharma Lp | Antagonisti trpv1 i njihova upotreba |
CA2685121A1 (en) | 2007-04-27 | 2008-11-06 | Purdue Pharma L.P. | Therapeutic agents useful for treating pain |
CA2719789A1 (en) | 2008-04-17 | 2009-10-22 | Pfizer Inc. | 4-benzylidene-3-methylpiperidine aryl carboxamide compounds useful as faah inhibitors |
ES2617619T3 (es) | 2008-06-05 | 2017-06-19 | Janssen Pharmaceutica, N.V. | Combinaciones de fármacos que comprenden un inhibidor de DGAT y un agonista de PPAR |
US8759362B2 (en) | 2008-10-24 | 2014-06-24 | Purdue Pharma L.P. | Bicycloheteroaryl compounds and their use as TRPV1 ligands |
US8703962B2 (en) | 2008-10-24 | 2014-04-22 | Purdue Pharma L.P. | Monocyclic compounds and their use as TRPV1 ligands |
US8546388B2 (en) | 2008-10-24 | 2013-10-01 | Purdue Pharma L.P. | Heterocyclic TRPV1 receptor ligands |
WO2011162409A1 (en) | 2010-06-22 | 2011-12-29 | Shionogi & Co., Ltd. | Compounds having trpv1 antagonistic activity and uses thereof |
-
2002
- 2002-01-25 KR KR1020037009856A patent/KR100777169B1/ko active IP Right Grant
- 2002-01-25 US US10/470,334 patent/US7867516B2/en not_active Expired - Lifetime
- 2002-01-25 EP EP02710352A patent/EP1356816B1/en not_active Expired - Lifetime
- 2002-01-25 DE DE60234812T patent/DE60234812D1/de not_active Expired - Lifetime
- 2002-01-25 JP JP2002560638A patent/JP4077320B2/ja not_active Expired - Fee Related
- 2002-01-25 AT AT02710352T patent/ATE452637T1/de not_active IP Right Cessation
- 2002-01-25 KR KR1020077018953A patent/KR100891887B1/ko active IP Right Grant
- 2002-01-25 WO PCT/JP2002/000544 patent/WO2002060446A1/ja active Application Filing
- 2002-01-29 TW TW091101440A patent/TWI314868B/zh not_active IP Right Cessation
-
2010
- 2010-11-08 US US12/941,994 patent/US20110104276A1/en not_active Abandoned
-
2011
- 2011-12-21 US US13/333,142 patent/US20120183615A1/en not_active Abandoned
-
2012
- 2012-10-26 US US13/662,221 patent/US9017722B2/en not_active Expired - Fee Related
-
2015
- 2015-03-27 US US14/671,251 patent/US20150209341A1/en not_active Abandoned
- 2015-11-24 US US14/951,313 patent/US9561217B2/en not_active Expired - Lifetime
-
2016
- 2016-12-20 US US15/385,451 patent/US20170100380A1/en not_active Abandoned
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101453688B1 (ko) * | 2013-11-05 | 2014-11-04 | 포항공과대학교 산학협력단 | 광 입사 각도 선택성을 가지는 전자 소자 및 그 제조 방법 |
WO2018160011A1 (ko) * | 2017-03-02 | 2018-09-07 | 영진약품 주식회사 | 피르페니돈의 입자크기 조절에 따른 타정성이 개선된 약제학적 조성물 및 이의 제조방법 |
Also Published As
Publication number | Publication date |
---|---|
US20160074375A1 (en) | 2016-03-17 |
EP1356816B1 (en) | 2009-12-23 |
TWI314868B (en) | 2009-09-21 |
JPWO2002060446A1 (ja) | 2004-05-27 |
WO2002060446A1 (en) | 2002-08-08 |
ATE452637T1 (de) | 2010-01-15 |
KR100891887B1 (ko) | 2009-04-03 |
EP1356816A4 (en) | 2005-02-09 |
KR100777169B1 (ko) | 2007-11-16 |
US20150209341A1 (en) | 2015-07-30 |
US20170100380A1 (en) | 2017-04-13 |
US9017722B2 (en) | 2015-04-28 |
KR20030072608A (ko) | 2003-09-15 |
US20040048902A1 (en) | 2004-03-11 |
DE60234812D1 (de) | 2010-02-04 |
US20130115288A1 (en) | 2013-05-09 |
EP1356816A1 (en) | 2003-10-29 |
US20120183615A1 (en) | 2012-07-19 |
US20110104276A1 (en) | 2011-05-05 |
JP4077320B2 (ja) | 2008-04-16 |
US9561217B2 (en) | 2017-02-07 |
US7867516B2 (en) | 2011-01-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100891887B1 (ko) | 5-메틸-1-페닐-2-(1h)-피리돈을 활성 성분으로서 함유하는의약 제제 | |
JP6092936B2 (ja) | 口腔内崩壊錠の製造方法 | |
JP4638964B2 (ja) | プロトンポンプ阻害剤およびnsaidからなる経口用医薬剤形 | |
JP4638561B2 (ja) | プロトンポンプ抑制剤を含有するマルチプルユニットの沸騰剤形 | |
JP4435424B2 (ja) | 口腔内で速やかに崩壊する錠剤 | |
EP1218889B1 (en) | Controlled release compositions comprising nimesulide | |
US20060153925A1 (en) | Novel solid pharmaceutical composition comprising amisulpride | |
KR20040098009A (ko) | 구강 내 속붕괴성 정제 | |
EP0749308B1 (en) | Film coated tablet of paracetamol and domperidone | |
RU2672573C2 (ru) | Фармацевтический комбинированный состав капсулы, содержащий тадалафил и тамсулозин | |
US4867987A (en) | Pharmaceutical product for the sustained release of ibuprofen | |
CZ280847B6 (cs) | Peroorálně aplikovatelná forma léku pro léčení centrálních stavů nedostatku dopaminu | |
US7135465B2 (en) | Sustained release beadlets containing stavudine | |
US20060159758A1 (en) | Coating composition for taste masking coating and methods for their application and use | |
JP2003300872A (ja) | 被覆固形催眠製剤 | |
EP0599767B1 (en) | Process to prepare water-dispersable tablets containing diclofenac | |
NZ207768A (en) | Sustained release tablets comprising dipyridamole | |
JPS6360926A (ja) | 感冒薬 | |
WO2019199136A1 (ko) | 붕해가 개선된 레날리도마이드의 경구용 정제 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A107 | Divisional application of patent | ||
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E601 | Decision to refuse application | ||
AMND | Amendment | ||
J201 | Request for trial against refusal decision | ||
E902 | Notification of reason for refusal | ||
B701 | Decision to grant | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130304 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20140228 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20150302 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20160303 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20170302 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20180316 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20190319 Year of fee payment: 11 |